Abstract
Ten patients with metastatic disease to the liver were treated with difluoromethylornithine (DFMO) administered by continuous hepatic arterial infusion. Two of nine evaluable patients had an objective partial response. Stable disease was recorded in three patients. Ototoxicity was encountered in all patients who received a daily dose of DFMO equal to or greater than 1.0 g/m2. Copyright © 1989 American Cancer Society
Cite
CITATION STYLE
Lipton, A., Harvey, H. A., Glenn, J., Weidner, W. A., Strauss, M., Miller, S. E., … Barlow, J. L. R. (1989). A phase I study of hepatic arterial infusion using difluoromethylornithine. Cancer, 63(3), 433–437. https://doi.org/10.1002/1097-0142(19890201)63:3<433::AID-CNCR2820630306>3.0.CO;2-5
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
